Clinical Trial Update: Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of pyrotinib in HER2-positive gastrointestinal tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Tumor

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: Gastrointestinal Tumor, Effect of Drug | Phase 2 | Status: UNKNOWN